GranuFlo and NaturaLyte News

Fresenius dialysis clinics forcing hospitals to close dialysis units despite quality concerns

April 23rd, 2014

Hospitals are being forced to close their dialysis units as Fresenius Medical Care (FMC) opens up new clinics, despite their quality concerns. Though in-patient treatment of dialysis in hospitals is thought to be safest, FMC is able to run its dialysis clinics for less money by paying staff less and putting in more patients per unit. More »

Influx of GranuFlo lawsuits expected as statute nears

March 25th, 2014

An influx of GranuFlo lawsuits are expected as the statute of limitations to claim injuries from GranuFlo and NaturaLyte nears. For some GranuFlo lawsuits, patients must file by March 2014, two years after Fresenius Medical Care issued its GranuFlo recall. However, some patients may be eligible to file as late as March 2018, depending on the state. More »

Fresenius opens clinic in southern Minnesota

January 21st, 2014

Fresenius Medical Care (FMC), which is currently in legal trouble for two of its products, has opened a dialysis clinic in rural southern Minnesota. More than 160,000 patients are estimated to use FMC dialysis clinics in the United States. More »

GranuFlo manufacturer receives second FDA warning letter

October 18th, 2013

Fresenius Medical Care, manufacturer of recalled GranuFlo and NaturaLyte dialysis acid concentrates, has received a second warning letter from the U.S. Food and Drug Administration. The first letter pertained to quality control at a facility in India, while the second pertains to quality at a facility in Puerto Rico. More »

FDA warns Fresenius to improve standards in facilities

September 26th, 2013

The U.S. Food and Drug Administration has warned international medical giant Fresenius Medical Care (FMC) to improve its operations and standards at a blood-bagging facility in Puerto Rico. The FDA’s complaints dealt specifically with the facility’s labeling procedures and how it was dealing with customer complaints. More »

FDA sends warning letter to Fresenius Medical Care over incomplete studies

March 28th, 2013

The U.S. Food and Drug Administration (FDA) has sent a warning letter to Fresenius Medical Care (FMC) concerning incomplete validation process for its equipment. The dialysis company failed to conduct adequate studies reviewing the quality of its equipment design, the FDA claimed. More »

Dialysis group creates new dialysis education center

January 24th, 2013

Dialysis awareness group Dialysis Patient Citizens has announced a new organization aimed at dialysis education called the Dialysis Patient Citizens Education Center. The Center will focus on education about dialysis and kidney diseases and issues. More »

Hissey Kientz launches new GranuFlo website

January 14th, 2013

Hissey Kientz law firm has launched a new GranuFlo and NaturaLyte website, http://www.granuflorecallhelp.com/, to provide patients with information concerning the recent class 1 GranuFlo and NaturaLyte recall. The website will provide frequently asked questions, side effects and news related to the recalled dialysis concentrates, as well as their manufacturer Fresenius Medical Care (FMC). More »

FDA releases serial numbers of recalled GranuFlo and NaturaLyte acid concentrates

December 13th, 2012

The Food and Drug Administration (FDA) has released serial numbers of the recently recalled GranuFlo and NaturaLyte acid concentrates. The drugs, which are used during hemodialysis treatment and were manufactured by Fresenius Medical Care (FMC), were initially recalled in March 2012. More »

GranuFlo manufacturer memo details deaths related to drug

October 19th, 2012

The manufacturer of the dialysis drug GranuFlo detailed the deaths and risks associated with the drug in an internal memo. Fresenius Medical Care (FMC) released the memo to doctors within its dialysis facilities in November 2011, but allegedly did not release it to other doctors or patients. More »

Page 1 of 212
I am currently represented by an attorney
*Required fields